Literature DB >> 20728343

Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression.

Martin Grimm1, Mia Kim, Andreas Rosenwald, Uwe Heemann, Christoph-Thomas Germer, Ana Maria Waaga-Gasser, Martin Gasser.   

Abstract

Toll-like receptor (TLR) stimulation results in activation of NF-κB, a key modulator in driving inflammation to cancer and mitogen-activated protein kinases that have been shown to recruit mitotic and cyclooxygenase-2 (COX-2) induced pathways in carcinogenesis. Here we asked whether different TLR, COX-2 and stem cell marker expression profiles in colorectal cancer (CRC) provide further evidence for this hypothesis from a clinical perspective. We analysed gene and protein expression of TLR7-TLR10, COX-2 and CD133 as a marker for colon-initiating cells in CRC patients (n=65). Gene analysis demonstrated significantly upregulated TLR7-TLR10 and COX-2 expression in CRC tumour tissues. Analysis of isolated tumour cells from primary tumours showed co-expression of TLR7 and TLR8 with CD133 and gave evidence for a subpopulation of colon cancer-initiating cells. In multivariate analyses TLR8 expression was found to be an independent prognostic factor. Persistent TLR-specific activation of NF-κB in CRC and particularly in tumour-initiating cells may thus sustain further tumour growth and progression through perpetuated signalling known from inflammatory and tissue repair mechanisms with consecutive self-renewal in pluripotent tumour cells. Activation through self-ligands or viral RNA fragments may putatively maintain this inflammatory process, suggesting a key role in cancer progression.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20728343     DOI: 10.1016/j.ejca.2010.07.017

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  23 in total

1.  Toll-like receptor expression pattern: clinical application.

Authors:  Shirin Moossavi; Nima Rezaei
Journal:  J Clin Immunol       Date:  2012-06-19       Impact factor: 8.317

2.  Glioblastoma Cancer Stem Cells Evade Innate Immune Suppression of Self-Renewal through Reduced TLR4 Expression.

Authors:  Alvaro G Alvarado; Praveena S Thiagarajan; Erin E Mulkearns-Hubert; Daniel J Silver; James S Hale; Tyler J Alban; Soumya M Turaga; Awad Jarrar; Ofer Reizes; Michelle S Longworth; Michael A Vogelbaum; Justin D Lathia
Journal:  Cell Stem Cell       Date:  2017-01-12       Impact factor: 24.633

3.  Toll-Like Receptor 4 and Matrix Metalloproteases 11 and 13 as Predictors of Tumor Recurrence and Survival in Stage II Colorectal Cancer.

Authors:  Noemi Eiro; Juan Francisco Carrión; Sandra Cid; Alejandro Andicoechea; José Luis García-Muñiz; Luis O González; Francisco J Vizoso
Journal:  Pathol Oncol Res       Date:  2019-02-01       Impact factor: 3.201

4.  Isolated lymphoid follicles in colon: switch points between inflammation and colorectal cancer?

Authors:  Ferenc Sipos; Györgyi Muzes
Journal:  World J Gastroenterol       Date:  2011-04-07       Impact factor: 5.742

5.  Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans.

Authors:  Atsuo Ochi; Christopher S Graffeo; Constantinos P Zambirinis; Adeel Rehman; Michael Hackman; Nina Fallon; Rocky M Barilla; Justin R Henning; Mohsin Jamal; Raghavendra Rao; Stephanie Greco; Michael Deutsch; Marco V Medina-Zea; Usama Bin Saeed; Melvin O Ego-Osuala; Cristina Hajdu; George Miller
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

Review 6.  Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis?

Authors:  Li Yu; Liantang Wang; Shangwu Chen
Journal:  Cell Mol Life Sci       Date:  2011-11-03       Impact factor: 9.261

7.  Synthesis and characterization of PEGylated toll like receptor 7 ligands.

Authors:  Michael Chan; Tomoko Hayashi; Richard D Mathewson; Shiyin Yao; Christine Gray; Rommel I Tawatao; Kevin Kalenian; Yanmei Zhang; Yuki Hayashi; Fitzgerald S Lao; Howard B Cottam; Dennis A Carson
Journal:  Bioconjug Chem       Date:  2011-02-21       Impact factor: 4.774

Review 8.  Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.

Authors:  Ting-Ting Li; Shuji Ogino; Zhi Rong Qian
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

Review 9.  Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence.

Authors:  S D Gowing; J J Cool-Lartigue; J D Spicer; A J E Seely; L E Ferri
Journal:  Clin Exp Metastasis       Date:  2020-01-23       Impact factor: 5.150

10.  Targeting Toll-like receptor 2 inhibits growth of head and neck squamous cell carcinoma.

Authors:  Lovisa Farnebo; Arash Shahangian; Yunqin Lee; June Ho Shin; Ferenc A Scheeren; John B Sunwoo
Journal:  Oncotarget       Date:  2015-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.